Dataset related to article "Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study "

This record contains raw data related to article "Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study" Abstract The aim of this study was to evaluate the clinical outcomes of a large series of brain metastatic renal cell carcinoma (BMRCC) patients treated in three Italian centers. Methods: A total of 120 BMRCC patients with a total of 176 lesions treated were evaluated. Patients received surgery plus postoperative HSRS, single-fraction SRS, or hypofractionated SRS (HSRS). Local control (LC), brain distant failure (BDF), overall survival (OS), toxicities, and prognostic factors were assessed. Results: The median follow-up time was 77 months (range 16-235 months). Surgery plus HSRS was performed in 23 (19.2%) cases, along with SRS in 82 (68.3%) and HSRS in 15 (12.5%). Seventy-seven (64.2%) patients received systemic therapy. The main total dose and fractionation used were 20-24 Gy in single fraction or 32-30 Gy in 4-5 daily fractions. Median LC time and 6 month and 1, 2 and 3 year LC rates were nr, 100%, 95.7% ± 1.8%, 93.4% ± 2.4%, and 93.4% ± 2.4%. Median BDF time and 6 month and 1, 2 and 3 year BDF rates were n.r., 11.9% ± 3.1%, 25.1% ± 4.5%, 38.7% ± 5.5%, and 44.4% ± 6.3%, respectively. Median OS time and 6 month and 1, 2 and 3 year OS rates were 16 months (95% CI: 12-22), 80% ± 3.6%, 58.3% ± 4.5%, 30.9% ± 4.3%, and 16.9% ± 3.6, respectively. No severe neurological toxicities occurred. Patients with a favorable/intermediate IMDC score, a higher RCC-GPA score, an early occurrence of BMs from primary diagnosis, absence of EC metastases, and a combined local treatment (surgery plus adjuvant HSRS) had a better outcome. Conclusions: SRS/HSRS is proven to be an effective local treatment for BMRCC. A careful evaluation of prognostic factors is a valid step to manage the optimal therapeutic strategy for BMRCC patients.本数据集包含与题为《肾细胞癌脑转移的多模态治疗：多中心回顾性研究结果》（Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study）的学术论文相关的原始数据。 摘要 本研究旨在评估意大利三家中心收治的大样本肾细胞癌脑转移（Brain Metastatic Renal Cell Carcinoma, BMRCC）患者的临床结局。 方法：本研究共纳入120例经治的肾细胞癌脑转移患者，共计176个脑转移病灶。患者接受的治疗方案包括手术联合术后大分割立体定向放射外科（Hypofractionated Stereotactic Radiosurgery, HSRS）、单次分割立体定向放射外科（Stereotactic Radiosurgery, SRS），或单纯大分割立体定向放射外科（HSRS）。评估指标包括局部控制率（Local Control, LC）、脑远处失败率（Brain Distant Failure, BDF）、总生存期（Overall Survival, OS）、不良反应及预后因素。 结果：中位随访时间为77个月（范围16~235个月）。其中23例（19.2%）患者接受了手术联合术后HSRS治疗，82例（68.3%）接受单次分割SRS治疗，15例（12.5%）接受HSRS治疗。77例（64.2%）患者接受了全身系统治疗。最常用的总剂量及分割方案为单次分割20~24 Gy，或分4~5次每日给予的30~32 Gy（原文32-30为排版笔误，调整为合理剂量顺序）。中位局部控制时间及6个月、1年、2年、3年局部控制率分别为未报道、100%、95.7%±1.8%、93.4%±2.4%及93.4%±2.4%。中位脑远处失败时间及6个月、1年、2年、3年脑远处失败率分别为未报道、11.9%±3.1%、25.1%±4.5%、38.7%±5.5%及44.4%±6.3%。中位总生存期为16个月（95%置信区间（Confidence Interval, CI）：12~22），6个月、1年、2年、3年总生存率分别为80%±3.6%、58.3%±4.5%、30.9%±4.3%及16.9%±3.6%。未发生严重神经系统不良反应。国际转移性肾细胞癌数据库联盟（International Metastatic Renal Cell Carcinoma Database Consortium, IMDC）评分良好/中等、肾细胞癌分级预后评分（Renal Cell Carcinoma-Graded Prognostic Assessment, RCC-GPA）更高、从原发肿瘤确诊至脑转移发生时间更早、无颅外转移（Extracranial Metastases, EC）以及接受联合局部治疗（手术联合辅助HSRS）的患者预后更佳。 结论：研究证实，SRS/HSRS是治疗肾细胞癌脑转移的有效局部治疗手段。对预后因素进行细致评估，可为肾细胞癌脑转移患者制定最优治疗策略提供可靠依据。